CA2599531A1 - Metformin methods and formulations for treating chronic constipation - Google Patents

Metformin methods and formulations for treating chronic constipation Download PDF

Info

Publication number
CA2599531A1
CA2599531A1 CA002599531A CA2599531A CA2599531A1 CA 2599531 A1 CA2599531 A1 CA 2599531A1 CA 002599531 A CA002599531 A CA 002599531A CA 2599531 A CA2599531 A CA 2599531A CA 2599531 A1 CA2599531 A1 CA 2599531A1
Authority
CA
Canada
Prior art keywords
metformin
formulation
release
pharmaceutically acceptable
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002599531A
Other languages
English (en)
French (fr)
Inventor
John Devane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGI Therapeutics Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2599531A1 publication Critical patent/CA2599531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002599531A 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation Abandoned CA2599531A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66292005P 2005-03-18 2005-03-18
US60/662,920 2005-03-18
PCT/IB2006/002233 WO2007007189A2 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Publications (1)

Publication Number Publication Date
CA2599531A1 true CA2599531A1 (en) 2007-01-18

Family

ID=37637555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002599531A Abandoned CA2599531A1 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Country Status (10)

Country Link
US (1) US20060222709A1 (enExample)
EP (1) EP1865939A2 (enExample)
JP (1) JP2008533127A (enExample)
AU (1) AU2006268003A1 (enExample)
CA (1) CA2599531A1 (enExample)
IL (1) IL185652A0 (enExample)
MX (1) MX2007011174A (enExample)
NO (1) NO20075344L (enExample)
WO (1) WO2007007189A2 (enExample)
ZA (1) ZA200707325B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) * 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) * 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2599789A1 (en) * 2011-12-01 2013-06-05 Bergen Teknologioverføring AS Marker and method for diagnosing diarrhea syndrome
CN104349773A (zh) * 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt) * 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
AU2013290100A1 (en) * 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
EP2941245B1 (en) * 2013-01-05 2024-06-26 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
CN104434846A (zh) * 2014-11-17 2015-03-25 中国药科大学 盐酸二甲双胍肠溶缓释微丸及其制备方法
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
EP4045520A1 (en) 2019-10-16 2022-08-24 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
JP2025535564A (ja) 2022-11-07 2025-10-24 リジュベネイト バイオメッド エヌブイ メトホルミンミニ錠剤
CN121846068A (zh) * 2023-08-22 2026-04-14 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
US20060222709A1 (en) 2006-10-05
EP1865939A2 (en) 2007-12-19
JP2008533127A (ja) 2008-08-21
ZA200707325B (en) 2009-03-25
WO2007007189A2 (en) 2007-01-18
AU2006268003A1 (en) 2007-01-18
MX2007011174A (es) 2008-02-11
NO20075344L (no) 2007-10-18
IL185652A0 (en) 2008-01-06
WO2007007189A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
US20060222709A1 (en) Metformin methods and formulations for treating chronic constipation
RU2207856C2 (ru) Способ лечения сердечно-сосудистых заболеваний
JP5783489B2 (ja) トロスピウムの１日１回剤形
US6156343A (en) Controlled release preparation
JP4072597B2 (ja) 持続性製剤
US20040202718A1 (en) Dosage form for treatment of diabetes mellitus
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
JPH061716A (ja) 活性成分の長期放出性を有する投薬形
US20070160671A1 (en) Biguanide formulations
US20190091156A1 (en) Milrinone controlled-release formulation
CN107530337A (zh) 治疗方法
AU2002351118B2 (en) Use of (R)-verapamil for the treatment of abnormal increases in gastrointestinal motility
US20060229261A1 (en) Acarbose methods and formulations for treating chronic constipation
EP1216032B1 (en) Oral controlled release formulations
KR100591142B1 (ko) 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
CN101516353B (zh) 包含核心和一个或多个阻挡层的控释口服制剂
EP3796908A1 (en) Controlled release propiverine formulations
WO2025242589A1 (en) Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy
AU2002348712A1 (en) Dosage form for treatment of diabetes mellitus
MXPA06004017A (es) Formas de dosis una vez al dia de trospio

Legal Events

Date Code Title Description
FZDE Discontinued